Affiliation:
1. Novartis Institutes for BioMedical Research, Emeryville, California, USA
Abstract
CUO246, a novel DNA gyrase/topoisomerase IV inhibitor, is active
in vitro
against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens and retains activity against quinolone-resistant strains in circulation. The frequency of selection for single step mutants of wild-type
S. aureus
with reduced susceptibility to CUO246 was <4.64 × 10
−9
at 4× and 8× MIC and remained low when using an isogenic QRDR mutant (<5.24 × 10
−9
at 4× and 8× MIC).
Funder
Novartis AG | Novartis Institutes for BioMedical Research
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology